Good points Danny3 and Slogger about not much news on new developments. I did note in the February results presentation that Acrux says "New Products - Formulation development in progress for new transdermal products - Licensing opportunities expected in 2013". So there is still hope for some action on that front this year. Perhaps there is a reason that Acrux hasn't given out any more information about this while they are negotiating.
The point of my post yesterday was that the upcoming earnings growth (from $2M in the last half year to my predicted $60M+ in FY14 and $100M+ in FY15) is about as "locked in" as you can get, and yet the market doesn't yet see this. Even if no other developments are announced, the value is clealy there. If other developments are announced (likely within 12 months IMO), then that is just extra blue sky.
ACR Price at posting:
$3.37 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)